Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
953.3 USD | +0.30% |
|
+2.39% | +63.80% |
02:35pm | Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793 | MT |
09:00am | Novo owner backs Swiss biotech Asceneuron in $100 million round | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.80% | 856B | |
+39.49% | 631B | |
-4.00% | 359B | |
+17.83% | 325B | |
+8.93% | 297B | |
+5.81% | 234B | |
+16.70% | 226B | |
+16.22% | 177B | |
+2.26% | 165B | |
+2.36% | 126B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793